2003
MADIT II patients with heart failure now eligible for Cardiac Resynchronization Therapy Defibrillator Indianapolis, IN and St. Paul, MN - Guidant Corporation (NYSE: GDT), a world leader in the...
Guidant''s Leadership in Heart Failure Therapy Continues with Landmark Study Indianapolis, IN and St. Paul, MN - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and...
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, announced today that it will conduct a live webcast of its annual...
Latest Defibrillator Expands Successful Product Portfolio Indianapolis, Ind. and St. Paul, Minn. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease,...
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, today announced that the company''s board of directors declared a fourth...
Agreement Reinforces Guidant''s Leadership in Endoscopic Cardiovascular Technologies Santa Clara, Calif. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular...
* Worldwide implantable defibrillator revenue of $385 million, up 48 percent * Worldwide stent revenue of $200 million, down 14 percent * Gross margin increases to 76.1 percent * Drug eluting...
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, will conduct a live webcast of its third quarter 2003 earnings conference...
Company Resumes Product Shipment with Food and Drug Administration Approval Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease,...
Cardiac Resynchronization Therapy Defibrillator Represents the World''s Thinnest, Most Advanced System Brussels, Belgium and St. Paul, Minn. - Guidant Corporation (NYSE: GDT), a world leader in...